|
AK2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.69580000042302E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.35609999966036E-07 |
| Normal-vs-Stage2 |
2.992400E-01 |
| Normal-vs-Stage3 |
3.80279999999678E-05 |
| Normal-vs-Stage4 |
1.617970E-03 |
| Stage1-vs-Stage2 |
9.578400E-02 |
| Stage1-vs-Stage3 |
6.624600E-01 |
| Stage1-vs-Stage4 |
9.319200E-01 |
| Stage2-vs-Stage3 |
8.762500E-02 |
| Stage2-vs-Stage4 |
1.847030E-01 |
| Stage3-vs-Stage4 |
8.219200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.14419998107496E-09 |
| Normal-vs-AfricanAmerican |
4.692600E-01 |
| Normal-vs-Asian |
1.656490E-03 |
| Caucasian-vs-AfricanAmerican |
9.912200E-02 |
| Caucasian-vs-Asian |
3.980200E-01 |
| AfricanAmerican-vs-Asian |
3.630200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.61580000000284E-05 |
| Normal-vs-Female |
6.59619999954231E-07 |
| Male-vs-Female |
9.617600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.47589999999853E-05 |
| Normal-vs-Age(41-60Yrs) |
1.93079999988299E-07 |
| Normal-vs-Age(61-80Yrs) |
1.441850E-03 |
| Normal-vs-Age(81-100Yrs) |
9.145000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.677200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.567600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.754400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.485000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.144200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.111600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.458500E-03 |
| Classical-VS-Follicular |
1.59354E-05 |
| Classical-VS-Other |
5.579200E-01 |
| Classical-VS-Normal |
2.82259993156231E-10 |
| Tall-VS-Follicular |
1.24440000526249E-08 |
| Tall-VS-Other |
5.383200E-01 |
| Tall-VS-Normal |
5.36160005282227E-12 |
| Follicular-VS-Other |
1.515700E-03 |
| Follicular-VS-Normal |
3.927800E-01 |
| Other-VS-Normal |
2.027300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.577500E-03 |
| Normal-vs-N1 |
2.52069999995275E-06 |
| N0-vs-N1 |
2.207600E-02 |
|
|
